February 21, 2017Circulation148 citations
View Full PaperImpact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor
Key Result
General use of the CardioMEMS sensor for hemodynamic-guided heart failure care led to significant lowering of pulmonary artery pressures, with greater reductions than in the CHAMPION trial.
Structured PICO
Does hemodynamic-guided heart failure care using the CardioMEMS sensor reduce pulmonary artery pressures in a general-use, nontrial setting?
P
Population
2000 general-use patients with heart failure
I
Intervention
Hemodynamic-guided heart failure care using implantable hemodynamic technology (CardioMEMS sensor)
C
Comparator
Patients from the pivotal CHAMPION clinical trial
O
Outcome
Reduction in pulmonary artery (PA) pressure over timesurrogate
General use of implantable hemodynamic technology in a real-world, nontrial setting leads to significant lowering of pulmonary artery pressures in heart failure patients.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
The first 2000 general-use patients managed with hemodynamic-guided heart failure care had higher PA pressures at baseline and experienced greater reduction in PA pressure over time compared with the pivotal CHAMPION clinical trial. These data demonstrate that general use of implantable hemodynamic technology in a nontrial setting leads to significant lowering of PA pressures.